Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

医学 2019年冠状病毒病(COVID-19) 安慰剂 2019-20冠状病毒爆发 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 伊马替尼 临床试验 梅德林 双盲 内科学 倍他科诺病毒 冠状病毒感染 重症监护医学 替代医学 病毒学 爆发 病理 传染病(医学专业) 法学 髓系白血病 疾病 政治学
作者
Jurjan Aman,Erik Duijvelaar,Liza Botros,Azar Kianzad,Job R. Schippers,Patrick J. Smeele,Sara Azhang,Imke Heleen Bartelink,Ahmed Abdallah Bayoumy,Pierre M. Bet,Wim G. Boersma,Peter Iwan Bonta,Karin A. Boomars,Lieuwe D. J. Bos,Job J.M.H. van Bragt,Gert‐Jan Braunstahl,Lucas R. Celant,Katrien A.B. Eger,J.J. Miranda Geelhoed,Yurika L E van Glabbeek
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (9): 957-968 被引量:121
标识
DOI:10.1016/s2213-2600(21)00237-x
摘要

BACKGROUND: The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak. METHODS: This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a peripheral oxygen saturation of greater than 94% were eligible. Patients were excluded if they had severe pre-existing pulmonary disease, had pre-existing heart failure, had undergone active treatment of a haematological or non-haematological malignancy in the previous 12 months, had cytopenia, or were receiving concomitant treatment with medication known to strongly interact with imatinib. Patients were randomly assigned (1:1) to receive either oral imatinib, given as a loading dose of 800 mg on day 0 followed by 400 mg daily on days 1-9, or placebo. Randomisation was done with a computer-based clinical data management platform with variable block sizes (containing two, four, or six patients), stratified by study site. The primary outcome was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours, while being alive during a 28-day period. Secondary outcomes included safety, mortality at 28 days, and the need for invasive mechanical ventilation. All efficacy and safety analyses were done in all randomised patients who had received at least one dose of study medication (modified intention-to-treat population). This study is registered with the EU Clinical Trials Register (EudraCT 2020-001236-10). FINDINGS: Between March 31, 2020, and Jan 4, 2021, 805 patients were screened, of whom 400 were eligible and randomly assigned to the imatinib group (n=204) or the placebo group (n=196). A total of 385 (96%) patients (median age 64 years [IQR 56-73]) received at least one dose of study medication and were included in the modified intention-to-treat population. Time to discontinuation of ventilation and supplemental oxygen for more than 48 h was not significantly different between the two groups (unadjusted hazard ratio [HR] 0·95 [95% CI 0·76-1·20]). At day 28, 15 (8%) of 197 patients had died in the imatinib group compared with 27 (14%) of 188 patients in the placebo group (unadjusted HR 0·51 [0·27-0·95]). After adjusting for baseline imbalances between the two groups (sex, obesity, diabetes, and cardiovascular disease) the HR for mortality was 0·52 (95% CI 0·26-1·05). The HR for mechanical ventilation in the imatinib group compared with the placebo group was 1·07 (0·63-1·80; p=0·81). The median duration of invasive mechanical ventilation was 7 days (IQR 3-13) in the imatinib group compared with 12 days (6-20) in the placebo group (p=0·0080). 91 (46%) of 197 patients in the imatinib group and 82 (44%) of 188 patients in the placebo group had at least one grade 3 or higher adverse event. The safety evaluation revealed no imatinib-associated adverse events. INTERPRETATION: The study failed to meet its primary outcome, as imatinib did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen. The observed effects on survival (although attenuated after adjustment for baseline imbalances) and duration of mechanical ventilation suggest that imatinib might confer clinical benefit in hospitalised patients with COVID-19, but further studies are required to validate these findings. FUNDING: Amsterdam Medical Center Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ZonMW, and the European Union Innovative Medicines Initiative 2.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Eidden_Zhang发布了新的文献求助10
刚刚
刚刚
刚刚
1秒前
司马秋凌完成签到,获得积分10
1秒前
少年完成签到,获得积分10
1秒前
WANG发布了新的文献求助30
1秒前
刘畅发布了新的文献求助10
1秒前
留胡子的书白完成签到,获得积分10
1秒前
骐骥完成签到,获得积分10
1秒前
过时的访天完成签到 ,获得积分10
2秒前
Junior完成签到,获得积分10
2秒前
常12发布了新的文献求助10
2秒前
Xxx完成签到,获得积分10
2秒前
明天更好发布了新的文献求助10
2秒前
qsny11完成签到 ,获得积分10
2秒前
不能没有科研完成签到,获得积分10
3秒前
ECHO完成签到 ,获得积分10
3秒前
lili发布了新的文献求助30
3秒前
rzVV完成签到,获得积分10
3秒前
ChenHao完成签到,获得积分10
4秒前
ghshen发布了新的文献求助30
4秒前
FKKKKSY完成签到,获得积分10
4秒前
4秒前
十驾医学僧完成签到,获得积分10
4秒前
Adriatic完成签到,获得积分10
4秒前
Tom完成签到,获得积分10
4秒前
活力的夜山完成签到,获得积分10
4秒前
张清泉发布了新的文献求助10
4秒前
愉快的平松完成签到,获得积分20
5秒前
mimilv发布了新的文献求助10
5秒前
he大海贼完成签到,获得积分10
5秒前
Akim的应助被小小赵采纳,获得10
5秒前
5秒前
光亮问凝完成签到,获得积分10
6秒前
6秒前
orixero的应助被yoyo采纳,获得10
7秒前
灰太狼完成签到 ,获得积分10
7秒前
慕青的应助被Amber采纳,获得10
8秒前
Sls7758258完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159542
求助须知:如何正确求助?哪些是违规求助? 9555044
关于积分的说明 21724263
捐赠科研通 7749434
什么是DOI,文献DOI怎么找? 3427246
关于科研通互助平台的介绍 2552263
邀请新用户注册赠送积分活动 2471618